Samsung Biologics issues RFP for W3tr IPO
Samsung Biologics has sent out a request for proposals for an up to W3tr ($2.6bn) listing in South Korea, according to a source close to the situation.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: